Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective The effectiveness of clozapine is clearly superior to other antipsychotics in the treatment of refractory schizophrenia. Clozapine leads to various side effects, and therefore many patients are forced to discontinue. In this study, we analyzed the registry database of all cases in Japan to identify risk factors for discontinuation of clozapine. Methods The Clozaril patient monitoring service® (CPMS) database from July 31, 2009 to January 26, 2020 was acquired. We defined the following exclusion criteria: patients who had ever taken clozapine by a non-CPMS method, such as an individual import or clinical trial, patients who did not receive clozapine after being enrolled in CPMS, and patients with initial doses other than 12.5 mg (outside the current protocol). Therefore, all patients in this study are new users. Multivariate Cox regression analysis was used to investigate independent risk factors associated with time to discontinuation of clozapine. Results We identified 8,263 patients as the study population. Clozapine discontinuation was significantly associated with age 40 and older [hazard ratio (HR)=1.66, p<0.001], intolerance to olanzapine (HR=1.31, p=0.018), previous treatment with clozapine (HR=1.30, p=0.001), and leukocyte counts <6,000/mm3 (HR=1.24, p<0.001). The Kaplan-Meier curves for clozapine discontinuation by age group revealed that older age at the time of clozapine introduction tended to have lower continuation rates. Conclusion Careful administration is important because patients with these factors have a high risk of discontinuation. In addition, the initiation of clozapine during the younger period was more effective and more tolerated.
Abstract
Objective The effectiveness of clozapine is clearly superior to other antipsychotics in the treatment of refractory schizophrenia. Clozapine leads to various side effects, and therefore many patients are forced to discontinue. In this study, we analyzed the registry database of all cases in Japan to identify risk factors for discontinuation of clozapine. Methods The Clozaril patient monitoring service® (CPMS) database from July 31, 2009 to January 26, 2020 was acquired. We defined the following exclusion criteria: patients who had ever taken clozapine by a non-CPMS method, such as an individual import or clinical trial, patients who did not receive clozapine after being enrolled in CPMS, and patients with initial doses other than 12.5 mg (outside the current protocol). Therefore, all patients in this study are new users. Multivariate Cox regression analysis was used to investigate independent risk factors associated with time to discontinuation of clozapine. Results We identified 8,263 patients as the study population. Clozapine discontinuation was significantly associated with age 40 and older [hazard ratio (HR)=1.66, p<0.001], intolerance to olanzapine (HR=1.31, p=0.018), previous treatment with clozapine (HR=1.30, p=0.001), and leukocyte counts <6,000/mm3 (HR=1.24, p<0.001). The Kaplan-Meier curves for clozapine discontinuation by age group revealed that older age at the time of clozapine introduction tended to have lower continuation rates. Conclusion Careful administration is important because patients with these factors have a high risk of discontinuation. In addition, the initiation of clozapine during the younger period was more effective and more tolerated.
참고문헌 (33)
- Chisholm D, "Schizophrenia treatment in the developing world : an interregional and multinational cost-effectiveness analysis", Bull World Health Organ, 86, pp.542~551 (2008)
- Provencher HL, "Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia", Schizophr Res, 26, pp.71~80 (1997)
- Hawton K, "Schizophrenia and suicide : systematic review of risk factors", Br J Psychiatry, 187, pp.9~20 (2005)
- Palmer CS, "A costeffectiveness clinical decision analysis model for schizophrenia", Am J Manag Care, 4, pp.345~355 (1998)
- Howes OD, "Treatment-resistant schizophrenia : Treatment Response and Resistance in Psychosis(TRRIP)working group consensus guidelines on diagnosis and terminology", Am J Psychiatry, 174, pp.216~229 (2017)
- Meltzer HY, "Treatment-resistant schizophrenia--the role of clozapine", Curr Med Res Opin, 14, pp.1~20 (1997)
- Taipale H, "20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62, 250patients with schizophrenia(FIN20)", World Psychiatry, 19, pp.61~68 (2020)
- Nucifora FC, "Clozapine as a model for antipsychotic development", Neurotherapeutics, 14, pp.750~761 (2017)
- Tiihonen J, "Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder : observational follow-up study", BMJ, 333, pp.224~ (2006)
- Essock SM, "Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals", Arch Gen Psychiatry, 57, pp.987~994 (2000)
- Bachmann CJ, "International trends in clozapine use : a study in 17 countries", Acta Psychiatr Scand, 136, pp.37~51 (2017)
- Xu SW, "Clozapine prescription pattern in patients with schizophrenia in Asia : The REAP survey(2016)", Psychiatry Res, 287, pp.112271~ (2020)
- Whiskey E, "Continuation of clozapine treatment : practice makes perfect", Psychiatr Bull, 27, pp.211~213 (2003)
- Knoph KN, "Clozapine-induced cardiomyopathy and myocarditis monitoring : a systematic review", Schizophr Res, 199, pp.17~30 (2018)
- Moeller FG, "Risk factors for clozapine discontinuation among 805 patients in the VA hospital system", Ann Clin Psychiatry, 7, pp.167~173 (1995)
- Krivoy A, "Predictors of clozapine discontinuation in patients with schizophrenia", Int Clin Psychopharmacol, 26, pp.311~315 (2011)
- Munro J, "Active monitoring of 12, 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance", Br J Psychiatry, 175, pp.576~580 (1999)
- Saito T, "Pharmacogenomic study of clozapine-induced agranulocytosis", granulocytopenia in a Japanese population, 2016, pp.80, 636~642
- Okhuijsen-Pfeifer C, "Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders : a systematic review and meta-analysis", Neurosci Biobehav Rev, 111, pp.246~252 (2020)
- Howard R, "Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis : an international consensus. The International Late-Onset Schizophrenia Group", Am J Psychiatry, 157, pp.172~178 (2000)
- Lieberman JA, "The early stages of schizophrenia : speculations on pathogenesis, pathophysiology, and therapeutic approaches", Biol Psychiatry, 50, pp.884~897 (2001)
- Lieberman JA, "Neurobiology and the natural history of schizophrenia", J Clin Psychiatry, 67, pp.e14~ (2006)
- Lee MA, "Effects of clozapine on cognitive function in schizophrenia", J Clin Psychiatry, 55(Suppl B), pp.82~87 (1994)
- McGurk SR, "The effects of clozapine on cognitive functioning in schizophrenia", J Clin Psychiatry, 60(Suppl 1), pp.24~29 (1999)
- Goldberg TE, "The effects of clozapine on neurocognition : an overview", J Clin Psychiatry, 55(Suppl B), pp.88~90 (1994)
- Legge SE, "Reasons for discontinuing clozapine : a cohort study of patients commencing treatment", Schizophr Res, 174, pp.113~119 (2016)
- Ascher-Svanum H, "Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia", BMC Psychiatry, 6, pp.8~ (2006)
- Ingimarsson O, "Clozapine treatment and discontinuation in Iceland : a national longitudinal study using electronic patient records", Nord J Psychiatry, 70, pp.450~455 (2016)
- Pillinger T, "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology : a systematic review and network meta-analysis", Lancet Psychiatry, 7, pp.64~77 (2020)
- McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163, pp.600~610 (2006)
- Littrell KH, "Switching clozapine responders to olanzapine", J Clin Psychiatry, 61, pp.912~915 (2000)
- Manu P, "Clozapine rechallenge after major adverse effects : clinical guidelines based on 259 cases", Am J Ther, 25, pp.e218~ (2018)
- Masuda T, "Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics : a systematic review and meta-analysis of cohort studies", JAMA Psychiatry, 76, pp.1052~1062 (2019)